Updated OPTIMIZE-1 results & biomarker analysis: mitazalimab shows promise in metastatic panc cancer

Karen Geboes, MD, PhD, UZ Ghent - University Hospital Gent, Gent, Belgium, reviews the updated results from the Phase Ib/II OPTIMIZE-1 trial (NCT04888312) and the biomarkers that confirm the mechanism of action for mitazalimab in patients with metastatic pancreatic cancer. The median progression-free survival (mPFS) of patients that responded to treatment was 58% at 12 months and 36% at 18 months. Biomarker analysis of responsive patients revealed that those with classical gene signature responded better to treatment. Higher levels of plasma blasts, CD54 monocytes, and myeloid dendritic cells were also associated to better performance of mitazalimab therapy and confirmed the theoretical mechanism of action for the drug. This interview took place at the 39th Annual Meeting of the Society for Immunotherapy of Cancer 2024, Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.